Maral Root for Health & Longevity - Quick Reference Sheet

Maral Root for Health & Longevity

Created on 08/25/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 Audit

A Siberian root whose main plant steroid enlarges muscle fibres without acting on the same receptor as testosterone. One training study found greater muscle and pressing-strength gains; another found none. Animal work on blood sugar, blood fats and blood-vessel inflammation has almost never been repeated in people. Products routinely contain far less than labelled, and some carry undeclared drugs. (Full Review)

Protocol

Standard extract protocol
200–500 mg daily
Root extract standardised to 5–10% 20-hydroxyecdysone, supplying roughly 10–50 mg of 20-hydroxyecdysone, taken continuously alongside resistance training
Best time of day
Morning
Before or shortly after training; keeps the compound's stimulant character away from the sleep window
Single versus split dosing
Split or single
The short half-life argues for splitting; supplement practice is usually a single morning dose and no head-to-head comparison of schedules exists
Time to effect
Muscle and strength
Around 8 weeks
Training studies measured change at 4, 8 and 10–12 weeks; the earliest separation from placebo appeared around 8 weeks
Giardia clearance
10 days
Complete clearance reported in one trial of purified 20-hydroxyecdysone, never replicated
Acute effect
None
Nothing supports an acute or within-days effect

Benefits

Contraindications
  • Pregnant or breastfeeding women
  • Estrogen-sensitive cancer (breast, endometrial, ovarian)
  • Athletes in national or international testing pools
  • Uncontrolled hypertension (resting blood pressure above 160/100 mmHg)
  • Seizure disorder
  • Therapeutic anticoagulation, or within 10 days of planned surgery
  • Advanced kidney impairment (eGFR below 30 mL/min/1.73 m²)
Key Interactions
  • Antiplatelet drugs (clopidogrel, low-dose aspirin)
  • Antihypertensives (lisinopril, amlodipine, bisoprolol)
  • Over-the-counter analgesics (ibuprofen, naproxen, aspirin)
  • Over-the-counter stimulants and decongestants (pseudoephedrine, high-dose caffeine)
  • Antiplatelet botanicals (ginkgo, garlic extract, high-dose fish oil, curcumin, nattokinase)
  • Stimulant adaptogens (Rhodiola rosea, Eleutherococcus senticosus, Panax ginseng)
  • Aggressive caloric restriction or a GLP-1 agonist

Risk & Side Effects

  • High: Ecdysteroid content far below the label claim; undeclared and prohibited drugs in sports supplements
  • Medium: Doping-control exposure for tested athletes
  • Low: Central stimulation, restlessness and disturbed sleep; blood pressure elevation in susceptible individuals; additive antiplatelet effect and bleeding risk; gastrointestinal intolerance
  • Speculative: Estrogen receptor beta activation in hormone-sensitive tissue; embryotoxicity signal in pregnancy and lactation; photosensitivity from root polyacetylenes

Monitoring

Marker Target Why
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ALT 10–26 U/L; AST 10–26 U/L Detects liver stress from an unregulated botanical or an undeclared contaminant
Estimated glomerular filtration rate (eGFR) and creatinine eGFR above 90 mL/min/1.73 m² Clearance is predominantly renal, so kidney function sets exposure
Fasting glucose 75–86 mg/dL Tracks the metabolic claim seen in animal work
Haemoglobin A1c (HbA1c) 4.8–5.3% Three-month average glucose; the stable counterpart to a fasting reading
Fasting insulin 2–5 µIU/mL The earliest marker to move if insulin sensitivity improves
High-sensitivity C-reactive protein (hs-CRP) Below 0.5 mg/L Tests the anti-inflammatory claim
Triglycerides and LDL cholesterol Triglycerides below 80 mg/dL; LDL cholesterol below 100 mg/dL Tests the lipid claim from the rodent metabolic work
Total testosterone and estradiol Men: testosterone 600–900 ng/dL, estradiol 20–30 pg/mL Confirms the absence of the hormonal shift seen with anabolic steroids
Insulin-like growth factor 1 (IGF-1) Mid-to-upper half of the age-specific reference range The one hormone that separated groups in the human training study
Resting blood pressure Below 120/80 mmHg The one traditional contraindication with a plausible mechanism
Lean body mass (DXA) No established target; track change from the individual's own baseline The primary endpoint the human evidence rests on

Cadence: Baseline one to two weeks before starting; liver and kidney panel repeated at 6–8 weeks; full set at 6 months and every 6–12 months thereafter if use continues; body composition and strength at 12 weeks; home blood pressure twice weekly for the first month.

Qualitative Assessment

  • Sleep onset latency and night waking, logged for the first two weeks, since central stimulation is the most likely early adverse signal
  • Session rating of perceived exertion at a fixed training load — the practical proxy for the fatigue-resistance claim
  • Training volume load (sets × reps × weight) per week, which is the honest test of whether anything changed
  • Subjective recovery between sessions and morning resting heart rate
  • Appetite and gastrointestinal comfort, the most commonly reported complaint in the trials